| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $15,511,198 | 6 | 100 |
| Mohideen Pharis | Chief Medical Officer | 0 | $0 | 4 | $27,055 | $-27,055 |
| EPIC Bpifrance | Member of 10% owner group | 0 | $0 | 2 | $15.48M | $-15.48M |
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and …
Over the last 12 months, insiders at DBV Technologies S.A. have bought $0 and sold $15.51M worth of DBV Technologies S.A. stock.
On average, over the past 5 years, insiders at DBV Technologies S.A. have bought $29,176 and sold $3.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,094 shares for transaction amount of $14,188 was made by Tasse Daniel (CHIEF EXECUTIVE OFFICER) on 2024‑03‑08.
| 2026-07-29 | Sale | Mohideen Pharis | Chief Medical Officer | 464 0.0004% | $2.70 | $1,253 | -10.71% | |
| 2026-01-29 | Sale | Mohideen Pharis | Chief Medical Officer | 534 0.0005% | $4.86 | $2,595 | -28.83% | |
| 2025-12-18 | Sale | EPIC Bpifrance | Member of 10% owner group | 1.29M 1.0517% | $4.19 | $5.41M | -19.05% | |
| 2025-12-17 | Sale | EPIC Bpifrance | Member of 10% owner group | 2.08M 1.8668% | $4.85 | $10.07M | -22.39% | |
| 2025-11-21 | Sale | Mohideen Pharis | Chief Medical Officer | 1,624 0.0014% | $2.77 | $4,498 | +26.11% | |
| 2025-11-20 | Sale | Mohideen Pharis | Chief Medical Officer | 6,496 0.0057% | $2.88 | $18,708 | +25.27% | |
| 2025-07-29 | Sale | Mohideen Pharis | Chief Medical Officer | 464 0.0004% | $2.22 | $1,030 | +73.27% | |
| 2025-05-22 | Sale | Mohideen Pharis | Chief Medical Officer | 397 0.0003% | $1.84 | $730 | +77.31% | |
| 2025-01-30 | Sale | Mohideen Pharis | Chief Medical Officer | 600 0.0006% | $0.85 | $510 | +128.87% | |
| 2024-11-25 | Sale | Mohideen Pharis | Chief Medical Officer | 565 0.0019% | $0.57 | $322 | +188.98% | |
| 2024-11-22 | Sale | Mohideen Pharis | Chief Medical Officer | 342 0.0011% | $0.53 | $181 | +205.08% | |
| 2024-11-21 | Sale | Mohideen Pharis | Chief Medical Officer | 2,350 0.0074% | $0.54 | $1,269 | +195.08% | |
| 2024-07-29 | Sale | Mohideen Pharis | Chief Medical Officer | 1,785 0.0103% | $0.98 | $1,749 | -15.13% | |
| 2024-05-24 | Sale | Mohideen Pharis | Chief Medical Officer | 660 0.0053% | $1.36 | $898 | -20.16% | |
| 2024-05-22 | Sale | Mohideen Pharis | Chief Medical Officer | 382 0.0031% | $1.38 | $527 | -21.37% | |
| 2024-03-08 | Tasse Daniel | CHIEF EXECUTIVE OFFICER | 17,094 0.0833% | $0.83 | $14,188 | -41.86% | ||
| 2024-02-06 | Ndu Adora | director | 1,825 0.0095% | $0.89 | $1,624 | -39.11% | ||
| 2023-11-22 | Sale | Mohideen Pharis | Chief Medical Officer | 2,245 0.0229% | $1.74 | $3,906 | -23.75% | |
| 2023-08-25 | MORRIS TIMOTHY E | director | 12,000 0.1071% | $1.52 | $18,240 | -46.31% | ||
| 2023-08-01 | SOLAND DANIEL B | director | 15,000 0.1426% | $1.62 | $24,300 | -47.83% |
| SOLAND DANIEL B | director | 20000 0.0836% | $202,200.00 | 1 | 0 | <0.0001% |
| Tasse Daniel | CHIEF EXECUTIVE OFFICER | 17094 0.0715% | $172,820.34 | 1 | 0 | <0.0001% |
| MORRIS TIMOTHY E | director | 12000 0.0502% | $121,320.00 | 1 | 0 | <0.0001% |
| Ndu Adora | director | 1825 0.0076% | $18,450.75 | 1 | 0 | <0.0001% |
$6,146,922 | 96 | -4.70% | $233.68M | |
$60,836,085 | 69 | 0.45% | $255.44M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 41 | +141.38% | 11M | +168.04% |
| Decreased Positions | 11 | -37.93% | 1M | -19.91% |
| New Positions | 26 | New | 5M | New |
| Sold Out Positions | 7 | Sold Out | 779,991 | Sold Out |
| Total Postitions | 59 | +103.45% | 16M | +148.13% |
| Baker Bros. Advisors Lp | $27,840.00 | 3.65% | 1.46M | 0 | 0% | 2025-09-30 |
| Vivo Capital, Llc | $20,088.00 | 2.64% | 1.05M | 0 | 0% | 2025-09-30 |
| Mpm Bioimpact Llc | $20,088.00 | 2.64% | 1.05M | 0 | 0% | 2025-09-30 |
| Octagon Capital Advisors Lp | $19,393.00 | 2.55% | 1.02M | 0 | 0% | 2025-09-30 |
| Yiheng Capital Management, L.P. | $12,503.00 | 1.64% | 656,309 | 0 | 0% | 2025-09-30 |
| Great Point Partners I Lp | $7,212.00 | 0.95% | 378,594 | +3,915 | +1.04% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $6,590.00 | 0.87% | 345,934 | -708,572 | -67.19% | 2025-09-30 |
| Millennium Management Llc | $6,436.00 | 0.85% | 337,863 | +69,849 | +26.06% | 2025-09-30 |
| Artisan Partners Limited Partnership | $989.00 | 0.13% | 51,920 | +51,920 | New | 2025-09-30 |
| Nan Fung Trinity (Hk) Ltd | $707.00 | 0.09% | 37,095 | 0 | 0% | 2025-09-30 |